A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2274 participants.
Also called NCT03689374
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,274 participants
- Sponsor
- Registry
-
NCT03689374 -
2017-003219-20
-
- Main results
- Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bosnia & Herzegovina, Bulgaria, Croatia, Czechia, Estonia, Germany, Greece, Hungary, India, Latvia, Lithuania, North Macedonia, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, South Africa, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT03689374. Randomized; no masking; primary purpose treatment. Start 2018-10-01 (actual); primary completion 2021-02-22 (actual). Results posted on 2022-05-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
- Acronym
- SUSTAIN 11
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Insulin aspart
- Intervention (Drug)
- Insulin glargine U100
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03689374- Content hash
2f0c226b54f38fb11d32f4d4499b0feb6f0a14d42df88d72e016960a7c6787c9